

BCCA Protocol Summary For Tamoxifen For Patients With Recurrent Desmoid Tumors/Aggressive Fibromatosis

Protocol Code *SATAM*

Tumour Group *Sarcoma*

Contact Physician *Dr. Meg Knowling*

ELIGIBILITY/TESTS:

Recurrent desmoid tumor or aggressive fibromatosis patients for whom other treatment modalities are not available.

TREATMENT:

Tamoxifen 20 mg PO bid

DOSE MODIFICATIONS:

Discontinue drug for severe side effects OR obvious progression of disease OR stabilisation of disease for six months.

PRECAUTIONS:

Women: hot flushes, vaginitis

Men: decrease in libido

Both: phlebitis, rare retinitis (reversible)

Allergy, rash, nausea and vomiting are very rare. In sarcoma patients any observed hematologic abnormality would be idiosyncratic and routine CBC's are not recommended.

MONITORING:

CT/MR every 3-6 months to monitor progress, UNLESS obvious clinical progression, then clinical discretion re: further imaging.

Call Dr. Meg Knowling or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

Date Activated:

Date last revised: 1 May 2009 (unsafe abbreviations and symbols replaced)